Cardiovascular effects of selective cyclooxygenase-2 inhibitors

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 2, 2004, Pages 265-270

  Krum, Henry ^a   Liew, Danny ^a   Aw, Juan ^a   Haas, Steven ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cardiovascular disease; Non steroidal anti inflammatory drugs; Review; Selective COX 2 inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; ICOSANOID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN G2; PROSTAGLANDIN H2; ROFECOXIB; THROMBOXANE A2;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY FAILURE; OSTEOARTHRITIS; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SODIUM DEPLETION; SODIUM RETENTION; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; WATER RETENTION;

CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE PROGRESSION; EPOPROSTENOL; HUMANS; LACTONES; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 2642586552     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.2.265     Document Type: Review

References (33)

1. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284(10), 1247-1255 (2000).
2. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343(21),1520-1528 (2000).
3. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345(6), 433-442 (2001).
4. Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104(19), 2280-2288 (2001).
5. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med. 162(10), 1111-1115 (2002).
6. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. 162(10), 1105-1110 (2002).
7. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med. 162(10), 1099-1104 (2002).
8. Van Hecken A, Schwartz JI, Depre M et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. 40, 1109-1120 (2000).
9. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359(9301), 118-123 (2002).
10. Ray WA, Stein CM, Daugherty JR et al. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360(9339), 1071-1073 (2002).
11. Mamdani M, Rochon P, Juurlink DN et al. Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch. Intern. Med. 163(4), 481-486 (2003).
12. Altman R, Luciardi HL, Muntaner J et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal anti-inflammatory drugs in Unstable angina Treatment-2 (NUT-2) pilot study. Circulation 106(2), 191-195 (2002).
13. Lipsky PE, Brooks P, Crofford LJ et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch. Intern. Med. 160(7), 913-920 (2000).
14. Whelton A. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. J. Hypertens. 20(Suppl. 6), S31-S35 (2002).
15. Whelton A, Fort JG, Puma JA et al. Cyclooxygenase-2-specific inhibitors and cardio-renal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 8(2), 85-95 (2001).
16. Whelton A, White WB, Bello AE et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. 90(9), 959-963 (2002).
17. Geba GP, Polis AB, Dixon ME et al. Comparative blood pressure effects of rofecoxib, celecoxib and placebo in patients with osteoarthritis: a randomized trial. Proc. EULAR Prague, Czech Republic. SAT0095 (2001).
18. National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure; National High Blood Pressure Education Program Co-ordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
19. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903-1913 (2002).
20. Safar ME. Pulse pressure, arterial stiffness and cardiovascular risk. Curr. Opin. Cardiol 15(4), 258-263 (2000).
21. Wilkinson IB, Cockcroft JR. Mind the gap: pulse pressure, cardiovascular risk and isolated systolic hypertension. Am. J. Hypertens. 13(12), 1315-1317 (2000).
22. Food and Drug Administration. Cardiovascular-renal safety review: Rofecoxib NDA 21-42 (1999).
23. Merck & Co Inc. VIOXX (rofecoxib) package insert. West Point, PA, USA (2001).
24. White WB, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 39(4), 929-934 (2002).
25. Liew D, Krum H. The role of aldosterone receptor blockade in the management of cardiovascular disease. Curr. Opin. Investig. Drugs 3(10), 1468-1473 (2002).
26. Libby F. Inflammation in atherosclerosis. Nature 420(6917), 868-874 (2002).
27. Baker CS, Hall RJ, Evans TJ et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vasc. Biol. 19, 646-655 (1999).
28. Schonbeck U, Sukhova GK, Graber P et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155, 1281-1291 (1999).
29. Saito T, Rodger IW, Hu E et al. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem. Biophys. Res. Commun. 273, 772-775 (2000).
30. Burleigh ME, Babaev VR, Oates JA et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105, 1816-1823 (2002).
31. Chenevard R, Hurlimann D, Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107(3), 405-409 (2003).
32. Widlansky ME, Price DT, Gokce N et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42(3), 310-315 (2003).
33. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J. Am. Coll. Cardiol. 42(10), 1747-1753 (2003).